Article
Oncology
Gary Hardiman, Stephen J. Savage, E. Starr Hazard, Willian A. da Silveira, Rebecca Morgan, Adam Harris, Melanie S. Jefferson, Robert C. Wilson, Susan Caulder, Linda Ambrose, Lewis Frey, Bethany Wolf, Sebastiano Gattoni-Celli, Chanita Hughes Halbert
Summary: Men of African origin have a higher likelihood of developing and dying from prostate cancer compared to men of European origin, with specific gene expression differences and clinical characteristics. This study identified a gene expression signature that separates African American men with the most severe clinical features, linking to elevated Gleason scores and vitamin D deficiency. Protein-protein interaction network analysis revealed a high degree of connectivity within genes associated with racial differences.
Article
Urology & Nephrology
Jennifer Cullen, Julie A. Lynch, Eric A. Klein, Stephen K. Van den Eeden, Peter R. Carroll, James L. Mohler, Dejan Knezevic, Thomas A. Farrington, Ruixiao Lu
Summary: A retrospective analysis was conducted to evaluate the performance of the Oncotype DX(R) Genomic Prostate Score(R) test in African American and Caucasian American men with surgically treated prostate cancer. The results showed that the assay was similarly predictive of outcomes in both racial groups, and improved risk stratification in men with newly diagnosed prostate cancer. Race was not found to be a significant predictor of adverse pathology or biochemical recurrence.
JOURNAL OF UROLOGY
(2021)
Article
Urology & Nephrology
Naoya Nagaya, Jeffrey Rosenfeld, Geun Taek Lee, Isaac Yi Kim
Summary: This study identified genetic differences in clinically localized prostate cancer in African American and Caucasian men through RNA sequencing, showing significant expression level differences in 45 genes. Pathway analysis revealed involvement of neuroactive ligand-receptor interaction and sphingosine-1-phosphate signaling. Validation in The Cancer Genome Atlas cohort showed significantly lower expression of cholinergic receptor muscarinic 3 in African American men with higher rates of biochemical recurrence.
PROSTATE INTERNATIONAL
(2021)
Article
Oncology
Maeve Kiely, Ginger L. Milne, Tsion Z. Minas, Tiffany H. Dorsey, Wei Tang, Cheryl J. Smith, Francine Baker, Christopher A. Loffredo, Clayton Yates, Michael B. Cook, Stefan Ambs
Summary: In this study, we found that high levels of TXB2 were associated with prostate cancer and poor outcomes in African American men, indicating a potential role of upregulated TXA2 synthesis in promoting disease progression and metastasis. Our findings suggest a potential benefit of aspirin in preventing lethal prostate cancer through inhibition of TXA2 synthesis, especially in high-risk populations like African American men.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE
(2022)
Article
Endocrinology & Metabolism
Julian Hazelton, Seongho Kim, Julie L. Boerner, Izabela Podgorski, Timothy Perk, Frank Cackowski, Hussein D. Aoun, Elisabeth I. Heath
Summary: The study aimed to investigate potential racial differences in the distribution of tumor metastases in the bone. The results showed that there were no significant differences in the location and number of bone metastases based on race among patients with metastatic prostate cancer. Therefore, African American patients might derive similar benefits from molecular imaging as non-African American patients, given equal access to the technology.
Article
Biochemistry & Molecular Biology
Anindita Ravindran, Danthasinghe Waduge Badrajee Piyarathna, Jie Gohlke, Vasanta Putluri, Tanu Soni, Stacy Lloyd, Patricia Castro, Subramaniam Pennathur, Jeffrey A. Jones, Michael Ittmann, Nagireddy Putluri, George Michailidis, Thekkelnaycke M. Rajendiran, Arun Sreekumar
Summary: African-American men are more likely to die of prostate cancer than European American men. This study reveals the association between lipid metabolic pathway alterations and prostate cancer disparities, as well as specific lipid changes associated with early biochemical recurrence.
Review
Oncology
Spyridon P. Basourakos, Michael Tzeng, Patrick J. Lewicki, Krishnan Patel, Bashir Al Hussein Al Awamlh, Siv Venkat, Jonathan E. Shoag, Michael A. Gorin, Christopher E. Barbieri, Jim C. Hu
Summary: Risk stratification for men with clinically localized prostate cancer has traditionally been based on basic clinicopathologic parameters. Recent focus has shifted towards developing tissue-based genomic tests to provide deeper insights into individual patient's disease risk. While these tests may impact patient and physician decision-making, their influence on oncologic outcomes is still uncertain. Multiple commercially available tests now offer additional prognostic information at various stages of prostate cancer care pathway.
FRONTIERS IN ONCOLOGY
(2021)
Article
Biochemistry & Molecular Biology
Swathi Ramakrishnan, Rick A. Kittles, Wendy J. Huss, Jianmin Wang, Kristopher Attwood, Anna Woloszynska
Summary: Dihydrotestosterone (DHT) and testosterone (T) play crucial roles in the proliferation and survival of prostate cancer cells. This study found significant differences in the serum levels of metabolites involved in DHT/T biosynthesis between African American (AA) and European American (EA) men with prostate cancer. The study also revealed higher frequencies of gene polymorphisms related to corticosterone-aldosterone conversion in AA men. Additionally, higher levels of T and pregnenolone were associated with a lower risk of progression-free survival only in AA men.
Article
Medicine, General & Internal
Margaret S. Pichardo, Tsion Zewdu Minas, Catherine M. Pichardo, Maeve Bailey-Whyte, Wei Tang, Tiffany H. Dorsey, William Wooten, Brid M. Ryan, Christopher A. Loffredo, Stefan Ambs
Summary: This study found that African American men living in deprived neighborhoods have a higher risk of prostate cancer and related mortality, potentially due to their systemic immune function and inflammation levels.
Article
Oncology
Shivanshu Awasthi, Anders Berglund, Julieta Abraham-Miranda, Robert J. Rounbehler, Kevin Kensler, Amparo Serna, Adriana Vidal, Sungyong You, Michael R. Freeman, Elai Davicioni, Yang Liu, R. Jeffrey Karnes, Eric A. Klein, Robert B. Den, Bruce J. Trock, Joshua D. Campbell, David J. Einstein, Raavi Gupta, Steven Balk, Priti Lal, Jong Y. Park, John L. Cleveland, Timothy R. Rebbeck, Stephen J. Freedland, Kosj Yamoah
Summary: Prostate tumors in African American men exhibit a unique immune profile with significant enrichment in proinflammatory immune pathways. The tumor microenvironment of African American men shows higher immune content compared to European American men, as well as lower DNA damage repair and increased genomic radiosensitivity. Overexpression of proinflammatory genes in African American men, such as IFITM3, is associated with higher risk of biochemical recurrence and poorer outcomes.
CLINICAL CANCER RESEARCH
(2021)
Article
Oncology
Matthew Epstein, Kaynaat Syed, John Danella, Serge Ginzburg, Laurence Belkoff, Jeffrey Tomaszewski, Edouard Trabulsi, Eric A. Singer, Bruce L. Jacobs, Jay D. Raman, Thomas J. Guzzo, Robert Uzzo, Adam C. Reese
Summary: This study found that African American men have a higher risk of prostate cancer recurrence and adverse pathology after radical prostatectomy compared to Caucasian men. According to the results, African American men may require closer post-operative surveillance and may be more likely to need additional treatments.
PROSTATE CANCER AND PROSTATIC DISEASES
(2023)
Article
Biology
Walter Rayford, Alp Tuna Beksac, Jordan Alger, Mohammed Alshalalfa, Mohsen Ahmed, Irtaza Khan, Ugo G. Falagario, Yang Liu, Elai Davicioni, Daniel E. Spratt, Edward M. Schaeffer, Felix Y. Feng, Brandon Mahal, Paul L. Nguyen, Robert B. Den, Mark D. Greenberger, Randy Bradley, Justin M. Watson, Matthew Beamer, Lambros Stamatakis, Darrell J. Carmen, Shivanshu Awasthi, Jonathan Hwang, Rachel Weil, Harri Merisaari, Nihal Mohamed, Leslie A. Deane, Dimple Chakravarty, Kamlesh K. Yadav, Kosj Yamoah, Sujit S. Nair, Ashutosh K. Tewari
Summary: Racial disparities in prostate cancer were investigated in a multi-institutional retrospective analysis of African-American and European-American men who underwent radical prostatectomy. Differences were found in gene expression with African-American men showing higher expression of inflammation genes and lower expression of mismatch repair genes.
COMMUNICATIONS BIOLOGY
(2021)
Article
Oncology
P. Travis Courtney, Rishi Deka, Nikhil Kotha, Daniel R. Cherry, Mia A. Salans, Tyler J. Nelson, Abhishek Kumar, Elaine Luterstein, Anthony T. Yip, Vinit Nalawade, J. Kellogg Parsons, A. Karim Kader, Tyler F. Stewart, Brent S. Rose
Summary: Outcomes were similar for African American and White men treated for low-intermediate-risk prostate cancer with active surveillance in the Veterans Affairs Health System.
Review
Oncology
Julieta Abraham-Miranda, Shivanshu Awasthi, Kosj Yamoah
Summary: Health disparities between American men of African and European descent can be attributed to various factors such as socioeconomic status, healthcare access, lifestyle, ancestry, and molecular aberrations. Clinical trials and research studies on prostate cancer are predominantly enrolling European descent men, potentially overlooking existing disparities between races. With advancements in immunotherapies, exploring immunological differences between ethnicities is crucial for developing innovative therapeutic approaches for prostate cancer globally.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
(2021)
Review
Endocrinology & Metabolism
Steven S. Coughlin, Marlo Vernon, Zachary Klaassen, Martha S. Tingen, Jorge E. Cortes
Summary: Recent studies show that many African American men lack knowledge about prostate cancer and early detection. This lack of knowledge is particularly prevalent among older, less-educated, lower-income, unmarried men, as well as those without regular healthcare or insurance. Culturally appropriate educational efforts are needed to inform African American men about these issues.
Article
Oncology
Xinglei Shen, Daniel E. Spratt, Stacie B. Dusetzina, Ronald C. Chen
Summary: This study evaluated the variation in commercial insurance coverage and its impact on access to cancer care. The analysis of coverage determinations across the nation revealed wide disparities in policy. The findings highlight the need for more consistent methodology in assessing medical necessity to address the unequal access to cancer procedures based on residence and age.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
(2023)
Article
Oncology
Soumyajit Roy, Yilun Sun, Cristopher J. D. Wallis, Scott C. Morgan, Scott Grimes, Julia Malone, Amar U. Kishan, Dibya Mukherjee, Daniel E. Spratt, Fred Saad, Shawn Malone
Summary: This study developed and validated a multivariable prognostic model to predict overall survival (OS) in metastatic castrate sensitive prostate cancer (mCSPC). The model includes 11 prognostic variables and showed high predictive accuracy on a testing set.
PROSTATE CANCER AND PROSTATIC DISEASES
(2023)
Article
Oncology
Richard L. Cantley, Xiaoming Wang, Zachery R. Reichert, Arul M. Chinnaiyan, Rahul Mannan, Xuhong Cao, Daniel E. Spratt, Ulka N. Vaishampayan, Joshi J. Alumkal, Todd M. Morgan, Ganesh Palapattu, Matthew S. Davenport, Liron Pantanowitz, Rohit Mehra
Summary: Fine needle aspiration (FNA) can be used to diagnose metastatic prostatic cancer (MPC) based on typical cytomorphologic and immunohistochemical (IHC) features, but the diagnosis may be complicated by atypical phenotypes induced by androgen deprivation therapy (ADT). Careful assessment of cytologic and biomarker features can provide important therapeutic and prognostic information in MPC.
CANCER CYTOPATHOLOGY
(2023)
Article
Oncology
Sagar A. Patel, Ting Martin Ma, Jessica K. Wong, Bradley J. Stish, Robert T. Dess, Avinash Pilar, Chandana Reddy, Trude B. Wedde, Wolfgang A. Lilleby, Ryan Fiano, Gregory S. Merrick, Richard G. Stock, D. Jeffrey Demanes, Brian J. Moran, Phuoc T. Tran, Daniel J. Krauss, Eyad I. Abu-Isa, Thomas M. Pisansky, C. Richard Choo, Daniel Y. Song, Stephen Greco, Curtiland Deville, Theodore L. DeWeese, Derya Tilki, Jay P. Ciezki, R. Jeffrey Karnes, Nicholas G. Nickols, Matthew B. Rettig, Felix Y. Feng, Alejandro Berlin, Jonathan D. Tward, Brian J. Davis, Robert E. Reiter, Paul C. Boutros, Tahmineh Romero, Eric M. Horwitz, Rahul D. Tendulkar, Michael L. Steinberg, Daniel E. Spratt, Michael Xiang, Amar U. Kishan
Summary: For very-high-risk prostate cancer patients, the addition of brachytherapy to external beam radiation therapy with androgen deprivation therapy did not significantly improve outcomes compared to radiation therapy alone.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
(2023)
Article
Pathology
Rahul Mannan, Xiaoming Wang, Pushpinder S. Bawa, Yuping Zhang, Stephanie L. Skala, Anya K. Chinnaiyan, Aniket Dagar, Lisha Wang, Sylvia B. Zelenka-Wang, Lisa M. McMurry, Nikita Daniel, Xuhong Cao, Ankur R. Sangoi, Sounak Gupta, Ulka N. Vaishampayan, Khaled S. Hafez, Todd M. Morgan, Daniel E. Spratt, Maria S. Tretiakova, Pedram Argani, Arul M. Chinnaiyan, Saravana M. Dhanasekaran, Rohit Mehra
Summary: LINC01187 is a novel biomarker that enhances the currently used KIT assay and facilitates microscopic analysis in routine surgical pathology practice.
INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY
(2023)
Article
Oncology
Ting Martin Ma, Yilun Sun, Shawn Malone, Mack Roach III, David Dearnaley, Thomas M. Pisansky, Felix Y. Feng, Howard M. Sandler, Jason A. Efstathiou, Isabel Syndikus, Emma C. Hall, Alison C. Tree, Matthew R. Sydes, Claire Cruickshank, Soumyajit Roy, Michel Bolla, Philippe Maingon, Theo De Reijke, Abdenour Nabid, Nathalie Carrier, Luis Souhami, Almudena Zapatero, Araceli Guerrero, Ana Alvarez, Carmen Gonzalez San-Segundo, Xavier Maldonado, Tahmineh Romero, Michael L. Steinberg, Luca F. Valle, Matthew B. Rettig, Nicholas G. Nickols, Jonathan E. Shoag, Robert E. Reiter, Nicholas G. Zaorsky, Angela Y. Jia, Jorge A. Garcia, Daniel E. Spratt, Amar U. Kishan
Summary: The sequencing of androgen-deprivation therapy (ADT) and radiotherapy (RT) may affect the outcome of prostate cancer depending on the size of the RT field. A study found that the sequencing of ADT has a significant impact on clinical outcomes for men receiving ADT with prostate-only RT (PORT) or whole-pelvis RT (WPRT).
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Oncology
Soumyajit Roy, Scott C. Morgan, Christopher J. D. Wallis, Yilun Sun, Daniel E. Spratt, Julia Malone, Scott Grimes, Dibya Mukherjee, Amar U. Kishan, Fred Saad, Shawn Malone
Summary: Pain is an important aspect of quality-of-life in mCSPC patients, but it is uncertain whether dynamic changes in pain over time can predict OS or rPFS. This study explores the association of dynamic changes in pain scores with OS and rPFS in mCSPC patients.
PROSTATE CANCER AND PROSTATIC DISEASES
(2023)
Article
Urology & Nephrology
Silke Gillessen, Alberto Bossi, Ian D. Davis, Johann de Bono, Karim Fizazi, Nicholas D. James, Nicolas Mottet, Neal Shore, Eric Small, Mathew Smith, Christopher Sweeney, Bertrand Tombal, Emmanuel S. Antonarakis, Ana M. Aparicio, Andrew J. Armstrong, Gerhardt Attard, Tomasz M. Beer, Himisha Beltran, Anders Bjartell, Pierre Blanchard, Alberto Briganti, Rob G. Bristow, Muhammad Bulbul, Orazio Caffo, Daniel Castellano, Elena Castro, Heather H. Cheng, Kim N. Chi, Simon Chowdhury, Caroline S. Clarke, Noel Clarke, Gedske Daugaard, Maria De, Ignacio Duran, Ros Eeles, Eleni Efstathiou, Jason Efstathiou, Onyeanunam Ngozi Ekeke, Christopher P. Evans, Stefano Fanti, Felix Y. Feng, Valerie Fonteyne, Nicola Fossati, Mark Frydenberg, Vvww Daniel, Martin Gleave, Gwenaelle Gravis, Susan Halabi, Daniel Heinrich, Ken Herrmann, Celestia Higano, Michael S. Hofmanfff, Lisa G. Horvath, Maha Hussain, Barbara Alicja Jereczek-Fossakkk, Robert Jonesmmm, Ravindran Kanesvaran, Pirkko-Liisa Kellokumpu-Lehtinen, Raja B. Khauli, Laurence Klotz, Gero Kramer, Raya Leibowitz, Christopher J. Logothetisp, Brandon A. Mahal, Fernando Maluf, Joaquin Mateo, David Matheson, Niven Mehra, Axel Merseburger, Alicia K. Morgans, Michael J. Morris, Hind Mrabti, Deborah Mukherji, Declan G. Murphy, Vedang Murthy, Paul L. Nguyen, William K. Oh, Piet Ost, Joe M. O'Sullivan, Anwar R. Padhani, Carmel Pezaro, Darren M. C. Poon, Colin C. Pritchard, Danny M. Rabah, Dana Rathkopf, Robert E. Reiter, Mark A. Rubin, Charles J. Ryan, Fred Saad, Juan Pablo Sade, Oliver A. Sartor, Howard Scher, Nima Sharifi, Iwona Skoneczna, Howard Soule, Daniel E. Spratt, Sandy Srinivas, Cora N. Sternberg, Thomas Steuber, Hiroyoshi Suzuki, Matthew R. Sydes, Mary-Ellen Taplin, Derya Tilki, Levent Turkeri, Fabio Turco, Hrioji Uemura, Hirotsugu Uemura, Yuksel Urun, Claire L. Vale, Inge van Oort, Neha Vapiwala, Jochen Walz, Kosj Yamoah, Dingwei Ye, Evan Y. Yu, Almudena Zapatero, Thomas Zilli, Aurelius Omlin
Summary: The voting results from the 2022 Advanced Prostate Cancer Consensus Conference provide valuable insights for clinical management in areas where high-level evidence is lacking. These results can guide physicians and patients in making treatment decisions and help prioritize future research.
Article
Oncology
Phuoc T. Tran, Kathryn Lowe, Hua-Ling Tsai, Daniel Y. Song, Arthur Y. Hung, Jason W. D. Hearn, Steven Miller, James A. Proudfoot, Matthew P. Deek, Ryan Phillips, Tamara Lotan, Channing J. Paller, Catherine H. Marshall, Mark Markowski, Shirl Dipasquale, Samuel Denmeade, Michael Carducci, Mario Eisenberger, Theodore L. DeWeese, Matthew Orton, Curtiland Deville, Elai Davicioni, Stanley L. Liauw, Elisabeth I. Heath, Stephen Greco, Neil B. Desai, Daniel E. Spratt, Felix Feng, Hao Wang, Tomasz M. Beer, Emmanuel S. Antonarakis
Summary: This study aimed to investigate the effect of enzalutamide on freedom from PSA progression in men with recurrent prostate cancer after radical prostatectomy. The results showed that enzalutamide monotherapy for 6 months in combination with salvage radiation therapy delayed PSA progression and was safe for high-risk patients with postoperative recurrence.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Medicine, General & Internal
Randy A. Vince, Ralph Jiang, Merrick Bank, Jake Quarles, Milan Patel, Yilun Sun, Holly Hartman, Nicholas G. Zaorsky, Angela Jia, Jonathan Shoag, Robert T. Dess, Brandon A. Mahal, Kristian Stensland, Nicholas W. Eyrich, Mariana Seymore, Rebecca Takele, Todd M. Morgan, Matthew Schipper, Daniel E. Spratt
Summary: This meta-analysis demonstrates that the interaction between race and social determinants of health (SDOH) is associated with racial disparities in prostate cancer outcomes. Black patients have higher prostate cancer-specific mortality (PCSM) than White patients in studies with minimal accounting for SDOH, but lower PCSM in studies with greater accounting for SDOH. The findings underscore the importance of considering SDOH variables in research to promote health equity.
Article
Oncology
Adam B. B. Weiner, Yang Liu, Alex Hakansson, Xin Zhao, James A. A. Proudfoot, Julian Ho, J. J. H. H. Zhang, Eric V. V. Li, R. Jeffrey Karnes, Robert B. B. Den, Amar U. U. Kishan, Robert E. E. Reiter, Anis A. A. Hamid, Ashely E. E. Ross, Phuoc T. T. Tran, Elai Davicioni, Daniel E. E. Spratt, Gerhardt Attard, Tamara L. L. Lotan, Melvin Lee Kiang Chua, Christopher J. J. Sweeney, Edward M. M. Schaeffer
Summary: A prostate subtyping classifier (PSC) was created by analyzing expression profiles from over 100,000 prostate tumors, identifying four subtypes with distinct biological and clinical features.
Article
Oncology
Silke Gillessen, Alberto Bossi, Ian D. Davis, Johann de Bono, Karim Fizazi, Nicholas D. James, Nicolas Mottet, Neal Shore, Eric Small, Matthew Smith, Christopher J. Sweeney, Bertrand Tombal, Emmanuel S. Antonarakis, Ana M. Aparicio, Andrew J. Armstrong, Gerhardt Attard, Tomasz M. Beer, Himisha Beltran, Anders Bjartell, Pierre Blanchard, Alberto Briganti, Rob G. Bristow, Muhammad Bulbul, Orazio Caffo, Daniel Castellano, Elena Castro, Heather H. Cheng, Kim N. Chi, Simon Chowdhury, Caroline S. Clarke, Noel Clarke, Gedske Daugaard, Maria De Santis, Ignacio Duran, Ross Eeles, Eleni Efstathiou, Jason Efstathiou, Onyeanunam Ngozi Ekeke, Christopher P. Evans, Stefano Fanti, Felix Y. Feng, Valerie Fonteyne, Nicola Fossati, Mark Frydenberg, Dan George, Martin Gleave, Gwenaelle Gravis, Susan Halabi, Daniel Heinrich, Ken Herrmann, Celestia Higano, Michael S. Hofman, Lisa G. Horvath, Maha Hussain, Barbara A. Jereczek-Fossa, Rob Jones, Ravindran Kanesvaran, Pirkko-Liisa Kellokumpu-Lehtinen, Raja B. Khauli, Laurence Klotz, Gero Kramer, Raja Leibowitz, Christopher Logothetis, Brandon Mahal, Fernando Maluf, Joaquin Mateo, David Matheson, Niven Mehra, Axel Merseburger, Alicia K. Morgans, Michael J. Morris, Hind Mrabti, Deborah Mukherji, Declan G. Murphy, Vedang Murthy, Paul L. Nguyen, William K. Oh, Piet Ost, Joe M. O'Sullivan, Anwar R. Padhani, Carmel J. Pezaro, Darren M. C. Poon, Colin C. Pritchard, Danny M. Rabah, Dana Rathkopf, Robert E. Reiter, Mark A. Rubin, Charles J. Ryan, Fred Saad, Juan Pablo Sade, Oliver Sartor, Howard I. Scher, Nima Sharifi, Iwona Skoneczna, Howard Soule, Daniel E. Spratt, Sandy Srinivas, Cora N. Sternberg, Thomas Steuber, Hiroyoshi Suzuki, Matthew R. Sydes, Mary-Ellen Taplin, Derya Tilki, Levent Turkeri, Fabio Turco, Hiroji Uemura, Hirotsugu Uemura, Yuksel Urun, Claire L. Vale, Inge van Oort, Neha Vapiwala, Jochen Walz, Kosj Yamoah, Dingwei Ye, Evan Y. Yu, Almudena Zapatero, Thomas Zilli, Aurelius Omlin
Summary: The APCCC 2022 addressed questions in various areas of advanced prostate cancer and provided voting results to supplement guidelines based on level 1 evidence. These results can assist clinicians, patients, research funders, and policy makers in making management decisions and identifying information gaps.
EUROPEAN JOURNAL OF CANCER
(2023)
Article
Urology & Nephrology
Soumyajit Roy, Yilun Sun, Scott C. Morgan, Christopher J. D. Wallis, Kevin King, Yu M. Zhou, Leah A. D'souza, Omar Azem, Adrianna E. Cueto-Marquez, Nathaniel B. Camden, Daniel E. Spratt, Amar U. Kishan, Fred Saad, Shawn Malone
Summary: This study investigated the influence of prior prostate-directed local therapy on first-line systemic therapy and survival in metastatic castrate-resistant prostate cancer (mCRPC) patients. The results showed that the efficacy and survival benefits of first-line abiraterone treatment did not significantly differ between patients who received prior local therapy and those who did not.
Correction
Health Care Sciences & Services
Andre J. Esteva, Jean Feng, Douwe van der Wal, Shih-Cheng Huang, Jeffry Simko, Sandy E. DeVries, Emmalyn Chen, Edward Schaeffer, Todd Morgan, Yilun Sun, Amirata A. Ghorbani, Nikhil Naik, Dhruv G. Nathawani, Richard D. Socher, Jeff L. Michalski, Mack R. Roach III, Thomas G. Pisansky, Jedidiah Monson, Farah A. Naz, James Wallace, Michelle M. Ferguson, Jean-Paul T. Bahary, James E. Zou, Matthew Lungren, Serena Y. Yeung, Ashley Ross, Howard M. Sandler, Phouc T. Tran, Daniel E. Spratt, Stephanie Pugh, Felix Y. Feng, Osama Mohamad
NPJ DIGITAL MEDICINE
(2023)
Article
Oncology
Clayton P. Smith, James A. Proudfoot, Paul C. Boutros, Robert E. Reiter, Luca Valle, Matthew B. Rettig, Nicholas G. Nickols, Felix Y. Feng, Paul L. Nguyen, Himanshu Nagar, Daniel E. Spratt, Gert Attard, Adam Weiner, Joanne B. Weidhaas, Jeremie Calais, T. Martin Ma, Elai Davicioni, Michael Xiang, Amar U. Kishan
Summary: PSMA PET has higher specificity and sensitivity than conventional imaging, and it can predict the risk of distant metastasis in high-risk and very high-risk prostate cancer patients. The risk of upstaging on PSMA PET is significantly correlated with the Decipher genetic score. Further studies are needed to explore the causal pathways between PSMA findings, Decipher scores, extraprostatic disease, and long-term clinical outcomes.
EUROPEAN UROLOGY ONCOLOGY
(2023)